NICOL MORSBY: Open Payments
NPI 1952813156 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 20 payments from 14 companies in 2025. Trend: 2023 $395 · 2024 $612 · 2025 $984
Food & beverage: $800Education: $184
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 5 | $269 |
| E.R. Squibb & Sons, L.L.C. | 1 | $124 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Gilead Sciences, Inc. | 2 | $106 |
| Daiichi Sankyo Inc. | 2 | $51 |
| SERVIER PHARMACEUTICALS LLC | 1 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Genentech USA, Inc. | 1 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
Products named: RYBREVANT, BREYANZI, OJJAARA, LIBTAYO, ERLEADA, Trodelvy, Enhertu, Oncaspar.
Industry payments across GA — which companies pay providers there.
